Driving Efficiencies in Life Sciences with Semaphore
Life Sciences organizations face many challenges; development costs are skyrocketing; government regulations are increasing; the business is demanding profitability for their shareholders. To remain competitive, companies must implement Semantic AI technologies to unlock the value in unstructured information to reduce organizational and regulatory exposure, decrease time and cost of new drug development, and make manufacturing processes more efficient.
Semaphore, our Semantic AI platform, supports Life Sciences and Biotech organizations R&D effectiveness, adverse event reporting, clinical trial management, real-world evidence, improved drug development as well as other initiatives. Semaphore enables organizations to reduce costs, improve speed to market, and accelerate innovation.
Extract relevant facts required for regulatory reporting
Discover patient journeys, treatment pathways, and market dynamics
Ensure medicines are delivered on time and in-transit spoilage is minimized
Decrease costs and increase drug speed to market
Identify drugs that will fail early - free up resources for other projects
Accelerate innovation cycles and avoid costly dead ends
One global biopharmaceutical organization with more than 30K employees located in 70 countries leveraged the power of Semantic AI and Semaphore to create a robust and extensible system that enables individuals to rapidly identify the appropriate standards, procedures, and responsibilities associated with their role to comply with organization and legal requirements.
For more information on how we can help you maximize the value of your data.Get in touch
Copyright © 2023 Progress Software Corporation and/or its subsidiaries or affiliates. All Rights Reserved.
Progress, Telerik, Ipswitch, Chef, Kemp, Flowmon, MarkLogic, Semaphore and certain product names used herein are trademarks or registered trademarks of Progress Software Corporation and/or one of its subsidiaries or affiliates in the U.S. and/or other countries. See Trademarks for appropriate markings.